MarketNewsUpdates.com News Commentary – https://www.bloomberg.com/press-releases/2017-10-26/evolution-in-technology-driven-medical-devices-booming-due-to-significant-technological-advancements
PR Newswire PALM BEACH, Florida, October 26, 2017
PALM BEACH, Florida, October 26, 2017 /PRNewswire/ —
Medical devices are expected to display notable growth in the coming years as a result of rising incidence of infectious diseases along with the rising popularity of non-invasive diagnostic practices. Various products available in the medical devices market are segmented into therapeutic devices, diagnostic and monitoring devices, and injury prevention and rehabilitation devices which are all expected to an exhibit excellent growth rate in the coming years as innovation and advancements in healthcare technologies pick up with a significant pace. According to Transparency Market Research, the future worth of the global diagnostic medical devices and mHealth monitoring market is to be around US$8 Billion in 2019. Its valuation in 2012 was around US$600 Million. If these figures hold true, the global diagnostic medical devices and mHealth monitoring market will exhibit a whopping CAGR of 43.30% between 2013 and 2019. Active healthcare stocks in the news today include BioSig Technologies, Inc. (OTC: BSGM), Intuitive Surgical Inc. (NASDAQ: ISRG), Mazor Robotics Ltd. (NASDAQ: MZOR), NuVasive Inc. (NASDAQ: NUVA), Baxter International Inc. (NYSE: BAX).
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has concluded a key part of the strategic planning project launched earlier this year in collaboration with Health Research International (HRI).
Project goals included understanding and presenting the clinical relevance of BioSig’s technology, pricing strategies, and envisioning optimal applications of BioSig’s platform technology beyond EP. As part of the study, HRI conducted a detailed survey of U.S. electrophysiologists primarily based in New York, Texas, Massachusetts, Florida, Pennsylvania and North Carolina. Among the factors interfering with effective ablations, the inability to record high-quality uipolar signals and difficulty detecting small intracardiac signals were consistently reported. Read this and more news for BioSig Technologies at: http://www.marketnewsupdates.com/news/bsgm.html Survey respondents rated all six features of PURE EP System as being ‘Very Helpful’ for their ablations, emphasizing overall noise reduction and improved signal clarity/accuracy as key benefits. Most respondents see signal clarity as paramount to the success of ablations and indicated interest in a technology that reduces ‘noise’. PURE EP System’s ability to shorten procedure time – including the ability to perform more complex ablations – was listed as its definitive economic benefit. These expected time savings were largely responsible for the attractive pricing recommended for PURE EP System. “The two key factors impacting the successful adoption of a new technology are that it addresses an unmet need and that its ability to fill that need is fairly easily understood. According to our survey results, PURE EP System meets both criteria. The unmet need is interference with the signals that drive complex EP ablation procedures; the solution is PURE EP’s ability to eliminate most “noise” and waveform interference, thereby enhancing signal breadth and clarity, and reducing the time required to perform these procedures,” commented Suzanne Ratzloff, President of Health Research International, about the survey results. “We are pleased with the results this study has delivered.
Having seen the impact that Health Research International has had on product launches for many established companies in our sector, we knew we were working with a gold standard in strategic planning and market forecasting. We have seen a consistent response amongst the EP community, which has confirmed our expectations for the clinical relevance of PURE EP System. Furthermore, we have seen that the assessment of PURE EP features increased with the size of the respondent’s complex ablations caseload, suggesting a greater appreciation of PURE EP among busier EP labs. This is an excellent outcome during this pivotal point in our Company’s business development, ” said Kenneth Londoner, Chairman & Chief Executive Officer of BioSig Technologies, Inc.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner
with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty-four hundred dollars for news coverage of the current press release issued by BioSig Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: Media Contact email: email@example.com +1-561-325-8757